Journal
TRENDS IN GENETICS
Volume 34, Issue 7, Pages 558-570Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tig.2018.04.004
Keywords
-
Categories
Funding
- Italian Foundation for Multiple Sclerosis [FISM 2015/R/09]
- Intramural Research Program of the National Institute on Aging, NIH [N01-AG-1-2109, HHSN271201100005C]
- European Union's Horizon 2020 Research and Innovation Program [633964]
- H2020 Societal Challenges Programme [633964] Funding Source: H2020 Societal Challenges Programme
Ask authors/readers for more resources
Choosing the right biological target is the critical primary decision for the development of new drugs. Systematic genetic association testing of both human diseases and quantitative traits, along with resultant findings of coincident associations between them, is becoming a powerful approach to infer drug targetable candidates and generate in vitro tests to identify compounds that can modulate them therapeutically. Here, we discuss opportunities and challenges, and infer criteria for the optimal use of genetic findings in the drug discovery pipeline.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available